Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study

Table 1 Demographic characteristics of the study subjects

	All N = 75488		With tamoxifen N = 50257		Without tamoxifen N = 25231
Variable	n	%	n	%	n	%	p-value
Age, years							<0.0001
<50	35715	47.3	25778	51.3	9937	39.4
50-59	21676	28.7	13124	26.1	8552	33.9
60-69	11353	15.0	7001	13.9	4352	17.6
70+	6744	8.93	4354	8.66	2390	9.47
Urbanization							0.34
Urban	50793	67.3	33874	67.4	16919	67.1
Rural	24695	32.7	16383	32.6	8312	32.9
Month income, NTD							<0.0001
<= 15000	12795	17.0	8231	16.4	4564	18.1
15001-20000	39463	52.3	26326	52.4	13137	52.1
>20000	33230	30.8	15700	31.2	7530	29.8
Comorbidity
Hypertension	21882	29.0	14142	28.1	7740	30.7	<0.0001
Hyperlipidemia	15458	20.5	9952	19.8	5506	21.8	<0.0001
Diabetes	8948	11.9	5698	11.3	3250	12.9	<0.0001
PAD	1477	1.96	905	1.80	572	2.27	<0.0001
Stroke	1715	2.27	1012	2.01	703	2.79	<0.0001
Osteoporosis	8024	10.6	5114	10.2	2910	11.5	<0.0001
Medicine, n (%)
HRT used before the index date	36690	48.6	24487	48.7	12203	48.4	0.35
Aromatase inhibitors used before the end point	20507	27.2	16273	32.4	4234	16.8	<0.0001